KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Non-Current Liabilities (2018 - 2025)

TherapeuticsMD (TXMD) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $10.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 11.89% year-over-year to $10.4 million, compared with a TTM value of $10.4 million through Sep 2025, down 11.89%, and an annual FY2024 reading of $10.7 million, down 20.01% over the prior year.
  • Total Non-Current Liabilities was $10.4 million for Q3 2025 at TherapeuticsMD, roughly flat from $10.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $272.7 million in Q1 2022 and bottomed at -$33.1 million in Q1 2023.
  • Average Total Non-Current Liabilities over 5 years is $91.0 million, with a median of $13.4 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities crashed 112.15% in 2023, then soared 138.6% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $261.0 million in 2021, then tumbled by 79.23% to $54.2 million in 2022, then plummeted by 75.31% to $13.4 million in 2023, then dropped by 20.01% to $10.7 million in 2024, then decreased by 3.29% to $10.4 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for TXMD at $10.4 million in Q3 2025, $10.4 million in Q2 2025, and $10.7 million in Q1 2025.